Clinical trial
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory…
NCT00316940 · Oncotherapeutics, Industry · Completed
Key facts
| NCT number | NCT00316940 |
|---|---|
| Title | Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Oncotherapeutics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug, Radiation |
| Interventions | bortezomib, samarium Sm 153 lexidronam pentasodium |
| Enrollment | 36 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Feb 1, 2011 |
| First posted | Apr 21, 2006 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: